Damora Therapeutics Inc. Common Stock (DMRA)

FairStock Score: 16/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Damora as a Graham-style analyst would: first ask what is proven. The answer is very little in financial terms. There is no revenue in the filed figures. In fiscal Q2 2026, the quarter ended 2026-06-30, net income was -$31.2 million. In fiscal Q1 2026, the quarter ended 2026-03-31, net income was -$27.8 million. For FY2025, net income was -$209.8 million, after -$21.4 million in FY2024 and -$38.3 million in FY2023. Trailing free cash flow is -$44.5 million, a -3.9% FCF yield on a $1.1 billion market cap. At the 2026-10-13 close of $18.56, FairStock shows a negative P/E of -71.38, P/B of 2.97, ROE of -99.74%, ROCE of -21.61%, Piotroski 0/9, and a FairStock Score of 16/100. The Lynch category is 'none' because it lost money in each of the last four years. The business may have scientific promise: DMR-001, DMR-002, DMR-003, and GB3226 target hematologic disorders. But I cannot identify a durable competitive moat from financials alone; there are no sales, no profits, and a seven-person workforce. The balance sheet has no debt (D/E 0.00) and a high Altman Z-Score of 24.66, but that is a FairStock calculation and not a substitute for earning power. Beta is 1.47 and the 52-week range is $4.95-$38.33, so the market is pricing binary hope, not steady cash flows. Graham would demand a margin of safety; here the valuation rests on future clinical success. Buffett would stay inside a circle of competence. I see a speculative venture, not a proven compounding business.

In plain English: Damora Therapeutics is a small biotech company trying to develop treatments for blood disorders. It has no revenue yet and has been losing money, including a net loss of $31.2 million in fiscal Q2 2026, the quarter ended 2026-06-30. At the 2026-10-13 close of $18.56, the price looks expensive against current financial results because there are no profits and cash is being used, so future value depends on drug trials succeeding.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer